{"schema":"sb.node.v1","id":"sb:e/6a808b32dabdbcd972d63a98","kind":"entity","label":{"text":"mounjaro","locale":"en"},"identity":{"anchor":"label:en:mounjaro","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T20:34:57.810068+00:00","snapshot":"deploy 93a668b9bf996ed1571cc113da6efcfab6db9d26"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":56,"separatePublishers":34,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-03","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.268: about 73% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","south_korea"],"activeDays":27,"assertions":{"utterance":4,"regulatory-approval":3,"price-threshold":2,"award":2,"acquisition":2,"launch-release":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/17c49facffcdcceb27271191","kind":"observation","label":"24/7 Wall St. · 2026-10-07 · Lilly’s Worst Entry Points Were Its Most Hyped Approvals Mounjaro and Zepbound","url":"https://247wallst.com/investing/2026/10/07/lillys-worst-entry-points-were-its-most-hyped-approvals-mounjaro-and-zepbound/"},{"id":"sb:o/efda0484e4cbfe6b0500ece8","kind":"observation","label":"Medical Daily · 2026-09-29 · FDA Flagged GLP-1 Vision Loss Signal in 2025, but U.S. Ozempic and Mounjaro Labels Still Lack NAION Warning","url":"https://www.medicaldaily.com/fda-glp1-naion-signal-us-label-warning-review-479225"},{"id":"sb:o/7238729f499957a26b02a9bd","kind":"observation","label":"Latest Science News -- ScienceDaily · 2026-09-27 · Zepbound and Mounjaro may turn on the body’s calorie-burning brown fat","url":"https://www.sciencedaily.com/releases/2026/09/260925093210.htm"},{"id":"sb:o/5f2a31c05c421aadbad343e6","kind":"observation","label":"Korea Times · 2026-09-22 · Wegovy, Mounjaro help Korean doctor navigate lifelong struggle with obesity","url":"https://www.koreatimes.co.kr/southkorea/health/20260922/wegovy-mounjaro-help-korean-doctor-navigate-lifelong-struggle-with-obesity?utm_source=rss"},{"id":"sb:o/27a54801e2c286bd5e2cd983","kind":"observation","label":"Seoul Economic Daily · 2026-10-08 · Korea's First Homegrown Obesity Drug Clears Approval, Launch Set for October","url":"https://en.sedaily.com/culture/2026/10/08/koreas-first-homegrown-obesity-drug-clears-approval-launch"},{"id":"sb:o/3768894e036a9e4240c8132b","kind":"observation","label":"Medical Xpress · 2026-10-07 · WHO says no obesity drugs, surgery for under-10s","url":"https://medicalxpress.com/news/2026-10-obesity-drugs-surgery-10s.html"},{"id":"sb:o/acdd3327df1a1c659af6ea90","kind":"observation","label":"TIME · 2026-10-07 · Compounding Pharmacies for Weight-Loss Drugs Are Booming. Should You Trust Them?","url":"https://time.com/article/2026/10/07/compounding-pharmacies-weight-loss-drugs/"},{"id":"sb:o/c44b0d820735233534e97994","kind":"observation","label":"MIT Technology Review · 2026-10-06 · Weight-loss drugs show signs of slowing biological aging, say drugmakers","url":"https://www.technologyreview.com/2026/10/06/1145836/weight-loss-drugs-glp1-lilly-novo-aging-clocks/"},{"id":"sb:o/1d000eb49b105a1a5321022c","kind":"observation","label":"Seoul Economic Daily · 2026-10-06 · Samsung Biologics Positions Itself as Key Partner for Blockbuster Drugs","url":"https://en.sedaily.com/finance/2026/10/06/samsung-biologics-positions-itself-as-key-partner-for"},{"id":"sb:o/66b55db08a35d1d7ea53c5d9","kind":"observation","label":"Seoul Economic Daily · 2026-10-06 · Korea's Adult Obesity Rate Hits Record 35.4%","url":"https://en.sedaily.com/culture/2026/10/06/koreas-adult-obesity-rate-hits-record-354-percent"}],"cursor":"c1.eyJpZCI6InNiOmUvNmE4MDhiMzJkYWJkYmNkOTcyZDYzYTk4IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA4VDIwOjM0OjU3LjgxMDA2OCswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with glp-1 (51 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/73192c912bb21678c37bcbc7"},{"kind":"relation","label":"co-mentioned with eli lilly (35 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/224d80574edb9b3ae8525f2f"},{"kind":"relation","label":"co-mentioned with zepbound (30 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1aad55717ea54b21c8655ef9"},{"kind":"relation","label":"co-mentioned with fda (17 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d001d0c6ea46c299d9eb5372"},{"kind":"relation","label":"co-mentioned with novo nordisk (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/574cb486fe1d9c6e6f166e37"},{"kind":"relation","label":"co-mentioned with glp-1s (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2114ce02b1179dfcf08de199"},{"kind":"relation","label":"co-mentioned with ai (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2a6e58992df4d9fa7185b38b"},{"kind":"relation","label":"co-mentioned with buy (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/33fe1c9493bdbbc2df774be3"},{"kind":"relation","label":"co-mentioned with denmark (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4ad7d4e3306d87393b00c580"},{"kind":"relation","label":"co-mentioned with foundayo (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/58e9362317f1602f707cbfa4"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/6a808b32dabdbcd972d63a98","mcp":"traverse {\"id\":\"sb:e/6a808b32dabdbcd972d63a98\"}","page":"/entity/mounjaro/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/6a808b32dabdbcd972d63a98\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/6a808b32dabdbcd972d63a98\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/6a808b32dabdbcd972d63a98\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/6a808b32dabdbcd972d63a98\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}